ArticleEuropean journal of heart failure2023
Ventricular stiffening and chamber contracture in heart failure with higher ejection fraction.
Article in European journal of heart failure, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 29 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
29 citing papers in PubMed, 61 citations in OpenAlex.
- Semaglutide and Exercise Function in Obesity-Related HFpEF: Insights From the STEP-HFpEF Program.JACC. Heart failure · 2025Trial
- Cardiac Myosin Inhibition in Heart Failure With Normal and Supranormal Ejection Fraction: Primary Results of the EMBARK-HFpEF Trial.JAMA cardiology · 2025Trial
- Effects of Continuous Accelerated Pacing on Cardiac Structure and Function in Patients With Heart Failure With Preserved Ejection Fraction: Insights From the myPACE Randomized Clinical Trial.Journal of the American Heart Association · 2024Trial
- Heart Failure with Supranormal Ejection Fraction: An Emerging High-Risk Phenotype Within the Preserved Ejection Fraction Spectrum-A Systematic Review.Journal of clinical medicine · 2026Review
- Effects of Tirzepatide in Obesity-Related HFpEF by Sex: A Prespecified Secondary Analysis From the SUMMIT Trial.JACC. Heart failure · 2026Article
- The HFpEF-ABA score predicts adverse cardiac remodelling and incident heart failure: a UK biobank study.ESC heart failure · 2026Article
- Hypercontractile phenotype at rest in chronic coronary syndromes predicts impaired functional reserve and increased mortality.ESC heart failure · 2026Article
- Heart Failure With Mildly Reduced Ejection Fraction: A Heart Failure Society of America Scientific Statement.Journal of cardiac failure · 2026Review
- Small left ventricular volume in HFpEF: from phenotype to clinical implications.ESC heart failure · 2026Article
- Left ventricular diastolic volume on cardiac magnetic resonance and risk of incident heart failure.European heart journal open · 2026Article
- Central Adiposity or Hypertension: Which Drives Heart Failure With a Preserved Ejection Fraction?Journal of the American College of Cardiology · 2025Review
- A Comprehensive Review: Unraveling the Role of Inflammation in the Etiology of Heart Failure.Heart failure reviews · 2025Review
- Clinical and plasma proteomic characterization of heart failure with supranormal left ventricular ejection fraction: An emerging entity of heart failure.European journal of heart failure · 2025Article
- Renal denervation in the setting of heart failure.Heart failure reviews · 2025Review
- Intracardiac energy inefficiency during decompensated and compensated heart failure.ESC heart failure · 2025Article
- Pathophysiological insights into HFpEF from studies of human cardiac tissue.Nature reviews. Cardiology · 2025Review
- 2024 update in heart failure.ESC heart failure · 2025Review
- Supra-Normal Ejection Fraction at Hospital Admission Stratifies Mortality Risk in HFpEF Patients Aged ≥ 70 Years.Journal of clinical medicine · 2025Article
- Small Heart Size and Premature Death in 366,484 Individuals With Normal Ejection Fraction.JACC. Advances · 2025Article
- Non-invasive estimation of left ventricular chamber stiffness using cardiovascular magnetic resonance and echocardiography.Journal of cardiovascular magnetic resonance : official journal of the Society for Cardiovascular Magnetic Resonance · 2025Article
Corrections and comments
- Commented on by
Authors and funding
9 authors at 3 institutions in 3 countries.
Funding
Abstract
aimsAncillary analyses from clinical trials have suggested reduced efficacy for neurohormonal antagonists among patients with heart failure and preserved ejection fraction (HFpEF) and higher ranges of ejection fraction (EF). METHODS AND
resultsA total of 621 patients with HFpEF were grouped into those with low-normal left ventricular EF (LVEF) (HFpEF
conclusionMost pathophysiologic differences in patients with HFpEF and higher EF are related to smaller heart size, increased LV diastolic stiffness, and leftward shift in the EDPVR. These findings may help to explain the absence of efficacy for neurohormonal antagonists in this group and raise a new hypothesis, that interventions to stimulate eccentric LV remodelling and enhance diastolic capacitance may be beneficial for patients with HFpEF and EF in the higher range.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.